The economic evaluation of personalised oncology medicines: ethical challenges

Area of Science:

• Oncology
• Pharmacoeconomics
• Molecular Biology

Background:

• Molecular insights are driving personalized cancer treatments.
• Targeted therapies like erlotinib and gefitinib show promise for advanced non-small cell lung cancer (NSCLC).
• Current treatments may be surpassed by targeted drugs in efficacy, safety, and tolerability for selected patients.

Purpose of the Study:

• To examine the challenges in assessing the cost-effectiveness of personalized oncology medicines in Australia.
• To propose a new framework for evaluating the value of personalized medicine.

Main Methods:

• Review of current treatment guidelines and reimbursement decisions.
• Analysis of pharmacoeconomic assessment frameworks.
• Ethical considerations in personalized medicine evaluation.

Main Results:

• First-line access to targeted therapies for advanced NSCLC is currently unfunded in Australia.
• The Pharmaceutical Benefits Advisory Committee has deemed these treatments not cost-effective.
• Significant evidentiary and ethical challenges exist in current cost-effectiveness assessments.

Conclusions:

• A novel approach is required to accurately determine the value and cost-effectiveness of personalized oncology medicines.
• Current assessment methods may not adequately capture the benefits of targeted cancer therapies.
• Addressing these challenges is crucial for equitable patient access to innovative treatments.